JP2014534262A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534262A5
JP2014534262A5 JP2014543554A JP2014543554A JP2014534262A5 JP 2014534262 A5 JP2014534262 A5 JP 2014534262A5 JP 2014543554 A JP2014543554 A JP 2014543554A JP 2014543554 A JP2014543554 A JP 2014543554A JP 2014534262 A5 JP2014534262 A5 JP 2014534262A5
Authority
JP
Japan
Prior art keywords
vaccine
hsv
polypeptide
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543554A
Other languages
English (en)
Japanese (ja)
Other versions
JP6199878B2 (ja
JP2014534262A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066241 external-priority patent/WO2013078299A1/en
Publication of JP2014534262A publication Critical patent/JP2014534262A/ja
Publication of JP2014534262A5 publication Critical patent/JP2014534262A5/ja
Application granted granted Critical
Publication of JP6199878B2 publication Critical patent/JP6199878B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543554A 2011-11-23 2012-11-21 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法 Expired - Fee Related JP6199878B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563507P 2011-11-23 2011-11-23
US61/563,507 2011-11-23
PCT/US2012/066241 WO2013078299A1 (en) 2011-11-23 2012-11-21 Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Publications (3)

Publication Number Publication Date
JP2014534262A JP2014534262A (ja) 2014-12-18
JP2014534262A5 true JP2014534262A5 (enExample) 2016-01-14
JP6199878B2 JP6199878B2 (ja) 2017-09-20

Family

ID=48470287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543554A Expired - Fee Related JP6199878B2 (ja) 2011-11-23 2012-11-21 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法

Country Status (6)

Country Link
US (1) US9624273B2 (enExample)
EP (1) EP2782597B1 (enExample)
JP (1) JP6199878B2 (enExample)
AU (1) AU2012340712B2 (enExample)
CA (1) CA2885693C (enExample)
WO (1) WO2013078299A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
NZ209308A (en) 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US5149529A (en) 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
WO1990013652A1 (en) 1989-05-12 1990-11-15 Triton Diagnostics, Inc. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
JP3005292B2 (ja) 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
DK31991D0 (da) 1991-02-25 1991-02-25 Carlbiotech Ltd As Peptid og farmaceutisk praeparat indeholdende et saadant peptid
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5955088A (en) * 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
JPH08510918A (ja) 1993-06-08 1996-11-19 アボツト・ラボラトリーズ 単純ヘルペスウィルス２型プロテアーゼ
CA2169748A1 (en) 1993-08-20 1995-03-02 Anthony G. Dilella Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) * 1994-07-25 1998-09-15 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6197497B1 (en) 1995-04-21 2001-03-06 University Of New Mexico Immunoassay for herpes simplex virus
US5654174A (en) 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
CA2269754A1 (en) 1996-10-23 1998-04-30 American Home Products Corporation Dna vaccines for herpes simplex virus 1 and 2
EP0948508A4 (en) 1996-11-04 2001-11-07 Smithkline Beecham Corp NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS
AU7597998A (en) * 1997-06-02 1998-12-21 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6054131A (en) 1998-01-16 2000-04-25 University Of Maryland Baltimore Vaccine composition for herpes simplex virus and method of using
ES2273482T3 (es) 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. Composiciones de vacunas combinadas.
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
JP2002522451A (ja) 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
EP1185662B1 (fr) 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6413518B1 (en) 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
DK1238086T3 (da) * 1999-12-17 2006-06-26 Wyeth Corp Vaccine til forögelse af immunreaktioner på herpes simplex virus
US7078388B2 (en) 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ATE349533T1 (de) 2000-06-29 2007-01-15 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
JP2004505113A (ja) 2000-07-27 2004-02-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 単純疱疹ウイルス糖蛋白質ｄを用いた組成物及びそれを用いて免疫応答を抑制する方法
EP1178111A1 (en) * 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
US20020094337A1 (en) 2000-11-16 2002-07-18 University Of Maryland, Baltimore Prevention of recurrent viral disease
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6814969B2 (en) 2001-07-31 2004-11-09 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
AU2002323443A1 (en) 2001-09-04 2003-03-18 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20030219448A1 (en) 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases
US20080299140A1 (en) 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
US7267940B2 (en) 2003-03-04 2007-09-11 Bio-Rad Laboratories, Inc. HSV-2 type-specific immunoassays using glycoprotein G2 peptides
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2006338570B2 (en) 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
CA2645507A1 (en) 2006-03-10 2007-09-20 The Regents Of The University Of California Vaccine for viruses that cause persistent or latent infections
EP2521786B1 (en) 2006-07-20 2015-06-24 Vical Incorporated Compositions for vaccinating against hsv-2
WO2008027394A2 (en) 2006-08-28 2008-03-06 The Wistar Institute Of Anatomy And Biology Constructs for enhancing immune responses
CA2663109A1 (en) 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsylvania Hsv-1 and hsv-2 vaccines and methods of use thereof
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
US9284355B2 (en) 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2009006618A2 (en) 2007-07-05 2009-01-08 University Of Kansas Herpes simplex virus mutant icp0 protein
WO2009006680A1 (en) 2007-07-06 2009-01-15 Sydney West Area Health Service Epitopes of herpes simplex virus
SE532551C2 (sv) 2008-06-30 2010-02-16 Senseair Ab Ett för spektralanalys anpassat arrangemang
US8313894B2 (en) * 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
WO2010078027A1 (en) * 2008-12-17 2010-07-08 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
AU2010249330B2 (en) * 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US9089537B2 (en) * 2010-02-26 2015-07-28 The Trustees Of The University Of Pennslyvania Subunit vaccines for herpes viruses and methods of use
US20130195961A1 (en) * 2010-03-09 2013-08-01 Kejian Yang Novel mucosal vaccination approach for herpes simplex virus type-2
CA2849391A1 (en) * 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
AU2011336894B2 (en) * 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response

Similar Documents

Publication Publication Date Title
US11471527B2 (en) Virus-like particles including HBs-L antigen protein for causing immune response against HBV
CN105906721B (zh) 一种水痘-带状疱疹病毒gB-gE-gH-gL融合蛋白、基因工程亚单位疫苗及制备方法
ES2224655T3 (es) Vacuna antiviral recombinante de la encefalitis equina venezolana.
JP2024545152A (ja) 単純ヘルペスウイルスｍＲＮＡワクチン
JP2012527486A5 (enExample)
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
JP2016128513A5 (enExample)
JP2015178529A5 (enExample)
Cong et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
Pourchet et al. CD8+ T-cell immune evasion enables oncolytic virus immunotherapy
CN111154806A (zh) 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
WO2022090679A1 (en) Coronavirus polypeptide
JP2019537555A5 (enExample)
Qi et al. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model
JP2014534262A5 (enExample)
Mohit et al. Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections
Molinelli et al. Biologic therapy in psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 pathways
Yi et al. Intranasal immunization with curdlan induce Th17 responses and enhance protection against enterovirus 71
JP2013545761A5 (enExample)
Zhang et al. ASFV subunit vaccines: Strategies and prospects for future development
WO2022105880A1 (zh) 融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用
Schulze et al. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus
CN102000330B (zh) 一种核酸疫苗佐剂及其构建方法
CN118873646A (zh) 一种抑制a组链球菌感染的重组蛋白疫苗及其应用